Literature DB >> 3533557

High dose therapy and autologous marrow transplantation as salvage treatment for patients with diffuse large cell lymphoma.

J O Armitage, S Jagannath, G Spitzer, P Bierman, A Kessinger, P Kumar, F Cabanillas, A Zander, L Vellekoop, K A Dicke.   

Abstract

Twenty-nine patients with diffuse large cell lymphoma who failed traditional chemotherapy were treated with high dose chemotherapy with or without total body irradiation followed by infusion of cryopreserved autologous marrow. Complete response was achieved in 11/29 patients (38%), partial response in 13/29 patients (45%) and 5/29 patients (17%) had no response. Six complete responders remain well and free of disease for 5+, 6+, 9+, 10+, 18+ and 25+ months, 3 relapsed at 2, 3 and 8 months after marrow infusion, and 2 died from infectious complications. Complete response was seen more frequently with the absence of bulky tumor (70 vs 21%, P = 0.03), a total body irradiation containing regimen (52 vs 0%, P = 0.03), a history of complete remission with initial chemotherapy (55% vs. 9%, P = 0.03), and a performance status greater than or equal to 80 (56 vs 15%, P = 0.06). High dose therapy had a high response rate (83%) in resistant diffuse large cell lymphoma and yielded durable complete responses in a minority of these patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533557     DOI: 10.1016/0277-5379(86)90376-7

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: two protocols.

Authors:  A D Elias; R Mazanet; C Wheeler; K Anderson; L Ayash; G Schwartz; I Tepler; S Pap; J Pelaez; M Hunt
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

Review 2.  Clinical applications of recombinant human colony-stimulating factors.

Authors:  H G Klingemann
Journal:  CMAJ       Date:  1989-01-15       Impact factor: 8.262

3.  Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.

Authors:  Jesús Duque-Afonso; Gabriele Ihorst; Miguel Waterhouse; Robert Zeiser; Ralph Wäsch; Hartmut Bertz; Mehtap Yücel; Thomas Köhler; Joachim Müller-Quernheim; Reinhard Marks; Jürgen Finke
Journal:  Bone Marrow Transplant       Date:  2020-06-26       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.